Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.38 Consensus Target Price from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given an average recommendation of “Buy” by the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have covered the stock in the last year is $6.38.

Several equities research analysts have weighed in on TSHA shares. BMO Capital Markets started coverage on shares of Taysha Gene Therapies in a research report on Thursday, June 27th. They set an “outperform” rating and a $5.00 price target for the company. Piper Sandler reduced their price target on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, July 1st. Needham & Company LLC lowered their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Chardan Capital reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group dropped their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Taysha Gene Therapies Stock Up 1.5 %

Shares of NASDAQ:TSHA opened at $2.06 on Friday. Taysha Gene Therapies has a 12-month low of $1.27 and a 12-month high of $4.32. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. The stock’s 50-day moving average price is $2.13 and its 200-day moving average price is $2.50. The stock has a market capitalization of $385.26 million, a P/E ratio of -4.20 and a beta of 0.40.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same period in the previous year, the firm earned ($0.38) EPS. On average, equities analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC grew its stake in shares of Taysha Gene Therapies by 328.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after buying an additional 14,294,445 shares in the last quarter. StemPoint Capital LP purchased a new stake in shares of Taysha Gene Therapies in the 1st quarter worth approximately $3,122,000. Bank of New York Mellon Corp bought a new stake in Taysha Gene Therapies during the 2nd quarter valued at $1,018,000. Rhumbline Advisers purchased a new position in Taysha Gene Therapies in the second quarter valued at about $413,000. Finally, Privium Fund Management B.V. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $213,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.